Lexeo Therapeutics, Inc. Income Statement
LXEO|1 years of annual SEC 10-K data (FY2023-FY2023)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Lexeo Therapeutics, Inc. reported $654,000 in revenue and $59M in net loss for FY2023. Its profit margin was -9063.8% in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 |
|---|---|
| Revenue | $654.0K |
| SG&A Expense | $12.0M |
| R&D Expense | $49.2M |
| Operating Income | -$60.5M |
| Interest Expense | $91.0K |
| Net Income | -$59.3M |
| EPS (Basic) | -$36.36 |
| EPS (Diluted) | -$36.36 |
| Shares Outstanding | 1.6M |
| Operating Margin | -9252.1% |
| Profit Margin | -9063.8% |